Multiple Myeloma Specific
http://www.jtcancercenter.org/[...]MultipleMyelomaDivision

General Website
http://www.kumed.com/

Multiple Myeloma Specific
http://www.kumed.com/healthwise/healthwise.aspx?DOCHWID=ncicdr0000258195

Description:
SNS01-T is a small inhibitory RNA molecule that blocks the expression of Factor 5A mRNA. The Factor 5A gene has been shown to regulate the expression of genes required for programmed cell death. SNS01-T is currently being developed for treatment of multiple myeloma for its potential to induce programmed cell death in cancerous cells.

Clinical Trials:
For a list of clinical trials studying SNS01-T for the treatment of multiple myeloma, see ClinicalTrials.gov.

Description:
IPH 2101 is a human antibody that helps activate cells of the immune system to destroy cancer cells. Specifically, IPH 2101 activates anti-tumor immune cells, known as natural killer cells, by blocking KIR inhibitory receptors on the surface of the immune cells. IPH 2101 is being studied in patients with smoldering myeloma, multiple myeloma, and acute myeloid leukemia.

Clinical Trials:
For a list of clinical trials studying IPH 2101 for the treatment of multiple myeloma, see ClinicalTrials.gov.

Official website for IPH2101: http://www.innate-pharma.com/therapeutic-area/iph-2101.

National Cancer Institute (NCI)
1-800-4-CANCER (1-800-422-6237)
http://www.cancer.gov/
http://www.cancer.gov/cancertopics/types/myeloma/

National Institutes of Health (NIH)
301-496-4000
Email: NIHinfo@od.nih.gov
http://www.nih.gov/
http://health.nih.gov/topic/MultipleMyeloma/Cancers

Summary

The NIH, a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. Helping to lead the way toward important medical discoveries that improve people’s health and save lives and composed of 27 Institutes and Centers, the NIH provides leadership and financial support to researchers in every state and throughout the world.

The NIH is headquartered in Bethesda, Maryland, just north of Washington, DC, and has satellite sites across the U.S. With the support of the American people, the NIH annually invests over $28 billion in medical research. Most of the NIH’s funding is awarded through competitive grants to researchers at over 3,000 universities, medical schools, and other research institutions in every state and around the world. About 10 percent of the NIH’s budget supports projects conducted by nearly 6,000 scientists in its own laboratories, most of which are on the NIH campus in Bethesda, Maryland.

The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and their families.

The Center for Cancer Research (CCR) is home to more than 250 scientists and clinicians working in intramural research at NCI. CCR is part of the Clinical Center at the NIH in Bethesda, Maryland, the largest hospital devoted entirely to clinical research in the U.S. The Clinical Center is a national resource that makes it possible to rapidly translate scientific observations and laboratory discoveries into new approaches for diagnosing, treating, and preventing disease. CCR’s investigators are basic, clinical, and translational scientists who work together to advance scientific knowledge and to develop new therapies.

Doctors

The following doctors specialize in hematology/oncology:

C. Ola Landgren, M.D., Ph.D. (websites: CCR Clinical Trials, Cancer for Research Center)
Specialty:
Hematology
Accomplishments:
Head, Multiple Myeloma Section Investigator
Youtube: http://www.youtube.com/watch?v=myc74Nmp9C0

More information on each doctor, including their current research and clinical trials, can be found on their respective Web pages.

Multiple Myeloma Research Team Contact Information

Mary Ann Yancey, R.N.
Research Nurse
yancey@mail.nih.gov
301-435-9227

Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping the growth of cancer cells. Several Phase 1 clinical trials have shown that AT9283 is safe in patients with blood and solid-tumor cancers, and pre-clinical studies have indicated that AT9283, alone or in combination with other myeloma treatments, is effective in multiple myeloma cells.

Clinical Trials:
For a list of clinical trials studying AT9283 for the treatment of multiple myeloma, see ClinicalTrials.gov.

Website for AT9283: http://www.astex-therapeutics.com/products/pipeline.php

Description:
ImMucin is a vaccine designed to stimulate the patient’s own immune system to kill cancer cells. ImMucin is a synthetic version of the important region of the MUC1 protein, which is made by more than 90 percent of common solid tumor cancers and many non-solid tumors, including multiple myeloma. ImMucin is designed to train the immune system to detect and kill cells that have MUC1 on their surface.

Clinical Trials:
For a list of clinical trials studying ImMucin for the treatment of multiple myeloma, see ClinicalTrials.gov.

Official website for BI-505: http://www.vaxilbio.com/…

Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, it is currently being investigated as a treatment of multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia.

Clinical Trials:
For a list of clinical trials studying milatuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov.

Official website for milatuzumab: http://www.immunomedics.com/5clinical/Milatuzumab.html

Description:
BT-062 (news articles) is a toxic drug bound to an antibody that helps deliver the treatment to myeloma and other cancer cells. When the compound enters a cancer cell, it releases the toxic drug that ultimately kills the cell. In a Phase 1 trial, BT-062 demonstrated an acceptable and manageable safety profile as well as evidence of clinical efficacy.

Clinical Trials:
For a list of clinical trials studying BT-062 for the treatment of multiple myeloma, see ClinicalTrials.gov.

Website for BT-062: http://www.biotest.de/ww/en/pub/biotherapeutics/bt___062/multiple_myeloma/biotherapeutic_agent_bt_062.cfm